Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)
NCT ID: NCT03813550
Last Updated: 2019-02-04
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-01-21
Study Completion Date
2020-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to demonstrate a potential association between gut microbiota composition, plasma levels of various forms of vitamin K, and severity of clinical manifestations of Pseudoxanthoma Elasticum (PXE).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Intestinal Microbiota on Uremic Toxins Productions
NCT04768309
CKD
Uremia
COMPLETED
NA
Gut Microbiota in Patients With Peripheral Arterial Disease and Chronic Limb-threatening Ischemia
NCT05757297
Peripheral Arterial Disease
NOT_YET_RECRUITING
Clinical Metagenomic of Post-traumatic Infections
NCT05770856
Fractures, Bone
Infections
COMPLETED
Gut Microbiota Association With ESBL-E Colonisation and Subsequent ESBL-E Infection
NCT04131569
Extended Spectrum Beta-Lactamase Producing Bacteria Infection
Microbial Colonization
Critical Illness
UNKNOWN
The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome
NCT03452189
End Stage Renal Disease
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Vitamin K deficiency contributes to pathological calcification which underlies the clinical picture of pseudoxanthoma elasticum (PXE), an inherited autosomal recessive disease. A substantial proportion of vitamin K, namely the K2 form (menaquinones), is produced by gut microbiota. In healthy volunteers fecal levels of the major menaquinone producers, Escherichia coli and Bacteroides species, are approximately 5 and 9 log10 CFU/g dry weight respectively. There is however a lack of data on gut microbiota in PXE patients. The objective of our project is to demonstrate a potential association between gut microbiota composition, plasma levels of various forms of vitamin K and severity of clinical manifestations in PXE patients.
This study will be performed as Research surrounding bio collection "Clinical and biological exploration of PXE patients" kept at the Center of Biological Resources of Angers University Hospital (bio collection n° DC 20116-14-67, authorization to transfer n° 2016-27-99). Fecal samples, plasma samples and clinical data will be collected from patients diagnosed with PXE who will be monitored at the Angers University Hospital Referral Center (France) in 2019-2020. Clinical severity of PXE will be assessed using modified Phenodex score. Gut microbiota will be analyzed using metagenomic sequencing. Plasma Vitamin K species and fecal excretion of menaquinones will be assessed using HPLC. Plasma dp-ucMGP (circulating biomarker of vitamin K status) and serum PIVKA-II (protein induced by vitamin K absence-II) will be assessed using immunoassay. Results will be compared to healthy age- and gender-matched controls from the pre-existing Biofortis database.
This study will be performed as Research surrounding bio collection "Clinical and biological exploration of PXE patients" kept at the Center of Biological Resources of Angers University Hospital (bio collection n° DC 20116-14-67, authorization to transfer n° 2016-27-99). Fecal samples, plasma samples and clinical data will be collected from patients diagnosed with PXE who will be monitored at the Angers University Hospital Referral Center (France) in 2019-2020. Clinical severity of PXE will be assessed using modified Phenodex score. Gut microbiota will be analyzed using metagenomic sequencing. Plasma Vitamin K species and fecal excretion of menaquinones will be assessed using HPLC. Plasma dp-ucMGP (circulating biomarker of vitamin K status) and serum PIVKA-II (protein induced by vitamin K absence-II) will be assessed using immunoassay. Results will be compared to healthy age- and gender-matched controls from the pre-existing Biofortis database.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pseudoxanthoma Elasticum
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PXE cohort 2019-2020
PXE patient cohort monitored at referral centre from 2019 to 2020: fecal and blood samples
Group Type
OTHER
Fecal and blood samples
Intervention Type
DIAGNOSTIC_TEST
Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fecal and blood samples
Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with phenotypically and genetically (ABCC6) proven PXE
* Aged over 18 years
* Written consent obtained for Angers University Hospital (France) PXE bio-collection
* Aged over 18 years
* Written consent obtained for Angers University Hospital (France) PXE bio-collection
Exclusion Criteria
* Patients under the age of 18
* Patients unwilling to participate in the study, or unable to sign the bio-collection consent form
* Patients unwilling to participate in the study, or unable to sign the bio-collection consent form
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht University
OTHER
Sponsor Role
collaborator
Biofortis Mérieux NutriSciences
OTHER
Sponsor Role
collaborator
University Hospital, Angers
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ludovic MARTIN, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Dermatology, University Hospital of Angers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biofortis Mérieux NutriSciences
Saint-Herblain, Pays de la Loire Region, France
Site Status
ACTIVE_NOT_RECRUITING
Department of Dermatology, University Hospital of Angers
Angers, Pays de Loire, France
Site Status
RECRUITING
Department of Biochemistry, University Maastricht
Maastricht, , Netherlands
Site Status
ACTIVE_NOT_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
France
Netherlands
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Carrillo-Linares JL, Garcia-Fernandez MI, Morillo MJ, Sanchez P, Rioja J, Baron FJ, Ariza MJ, Harrington DJ, Card D, Boraldi F, Quaglino D, Valdivielso P. The Effects of Parenteral K1 Administration in Pseudoxanthoma Elasticum Patients Versus Controls. A Pilot Study. Front Med (Lausanne). 2018 Apr 16;5:86. doi: 10.3389/fmed.2018.00086. eCollection 2018.
Reference Type
BACKGROUND
Brampton C, Yamaguchi Y, Vanakker O, Van Laer L, Chen LH, Thakore M, De Paepe A, Pomozi V, Szabo PT, Martin L, Varadi A, Le Saux O. Vitamin K does not prevent soft tissue mineralization in a mouse model of pseudoxanthoma elasticum. Cell Cycle. 2011 Jun 1;10(11):1810-20. doi: 10.4161/cc.10.11.15681. Epub 2011 Jun 1.
Reference Type
BACKGROUND
Karlsson FH, Fak F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Backhed F, Nielsen J. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. doi: 10.1038/ncomms2266.
Reference Type
BACKGROUND
Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Varadi A, Plomp A, Bergen AA, Oude Elferink RP, Borst P, van de Wetering K. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1985-9. doi: 10.1161/ATVBAHA.114.304017. Epub 2014 Jun 26.
Reference Type
BACKGROUND
Jansen RS, Kucukosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman IE, Bergen AA, Gorgels TG, Borst P, van de Wetering K. ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20206-11. doi: 10.1073/pnas.1319582110. Epub 2013 Nov 25.
Reference Type
BACKGROUND
Pomozi V, Brampton C, van de Wetering K, Zoll J, Calio B, Pham K, Owens JB, Marh J, Moisyadi S, Varadi A, Martin L, Bauer C, Erdmann J, Aherrahrou Z, Le Saux O. Pyrophosphate Supplementation Prevents Chronic and Acute Calcification in ABCC6-Deficient Mice. Am J Pathol. 2017 Jun;187(6):1258-1272. doi: 10.1016/j.ajpath.2017.02.009. Epub 2017 Apr 14.
Reference Type
BACKGROUND
Gheduzzi D, Boraldi F, Annovi G, DeVincenzi CP, Schurgers LJ, Vermeer C, Quaglino D, Ronchetti IP. Matrix Gla protein is involved in elastic fiber calcification in the dermis of pseudoxanthoma elasticum patients. Lab Invest. 2007 Oct;87(10):998-1008. doi: 10.1038/labinvest.3700667. Epub 2007 Aug 27.
Reference Type
BACKGROUND
Hendig D, Zarbock R, Szliska C, Kleesiek K, Gotting C. The local calcification inhibitor matrix Gla protein in pseudoxanthoma elasticum. Clin Biochem. 2008 Apr;41(6):407-12. doi: 10.1016/j.clinbiochem.2007.12.023. Epub 2008 Jan 11.
Reference Type
BACKGROUND
Li Q, Jiang Q, Schurgers LJ, Uitto J. Pseudoxanthoma elasticum: reduced gamma-glutamyl carboxylation of matrix gla protein in a mouse model (Abcc6-/-). Biochem Biophys Res Commun. 2007 Dec 14;364(2):208-13. doi: 10.1016/j.bbrc.2007.09.122. Epub 2007 Oct 4.
Reference Type
BACKGROUND
Vanakker OM, Martin L, Schurgers LJ, Quaglino D, Costrop L, Vermeer C, Pasquali-Ronchetti I, Coucke PJ, De Paepe A. Low serum vitamin K in PXE results in defective carboxylation of mineralization inhibitors similar to the GGCX mutations in the PXE-like syndrome. Lab Invest. 2010 Jun;90(6):895-905. doi: 10.1038/labinvest.2010.68. Epub 2010 Apr 5.
Reference Type
BACKGROUND
Gorgels TG, Waarsing JH, Herfs M, Versteeg D, Schoensiegel F, Sato T, Schlingemann RO, Ivandic B, Vermeer C, Schurgers LJ, Bergen AA. Vitamin K supplementation increases vitamin K tissue levels but fails to counteract ectopic calcification in a mouse model for pseudoxanthoma elasticum. J Mol Med (Berl). 2011 Nov;89(11):1125-35. doi: 10.1007/s00109-011-0782-y. Epub 2011 Jul 2.
Reference Type
BACKGROUND
Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J Nutr. 1996 Apr;126(4 Suppl):1181S-6S. doi: 10.1093/jn/126.suppl_4.1181S.
Reference Type
BACKGROUND
Ramotar K, Conly JM, Chubb H, Louie TJ. Production of menaquinones by intestinal anaerobes. J Infect Dis. 1984 Aug;150(2):213-8. doi: 10.1093/infdis/150.2.213.
Reference Type
BACKGROUND
Shearer MJ. Vitamin K. Lancet. 1995 Jan 28;345(8944):229-34. doi: 10.1016/s0140-6736(95)90227-9. No abstract available.
Reference Type
BACKGROUND
Walther B, Karl JP, Booth SL, Boyaval P. Menaquinones, bacteria, and the food supply: the relevance of dairy and fermented food products to vitamin K requirements. Adv Nutr. 2013 Jul 1;4(4):463-73. doi: 10.3945/an.113.003855.
Reference Type
BACKGROUND
Bentley R, Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiol Rev. 1982 Sep;46(3):241-80. doi: 10.1128/mr.46.3.241-280.1982. No abstract available.
Reference Type
BACKGROUND
Conly JM, Stein K. The production of menaquinones (vitamin K2) by intestinal bacteria and their role in maintaining coagulation homeostasis. Prog Food Nutr Sci. 1992 Oct-Dec;16(4):307-43.
Reference Type
BACKGROUND
Beulens JW, Booth SL, van den Heuvel EG, Stoecklin E, Baka A, Vermeer C. The role of menaquinones (vitamin K(2)) in human health. Br J Nutr. 2013 Oct;110(8):1357-68. doi: 10.1017/S0007114513001013. Epub 2013 Apr 16.
Reference Type
BACKGROUND
Conly JM, Stein K. Quantitative and qualitative measurements of K vitamins in human intestinal contents. Am J Gastroenterol. 1992 Mar;87(3):311-6.
Reference Type
BACKGROUND
Schurgers LJ, Teunissen KJ, Hamulyak K, Knapen MH, Vik H, Vermeer C. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007 Apr 15;109(8):3279-83. doi: 10.1182/blood-2006-08-040709. Epub 2006 Dec 7.
Reference Type
BACKGROUND
Suttie JW. The importance of menaquinones in human nutrition. Annu Rev Nutr. 1995;15:399-417. doi: 10.1146/annurev.nu.15.070195.002151.
Reference Type
BACKGROUND
Usui Y, Tanimura H, Nishimura N, Kobayashi N, Okanoue T, Ozawa K. Vitamin K concentrations in the plasma and liver of surgical patients. Am J Clin Nutr. 1990 May;51(5):846-52. doi: 10.1093/ajcn/51.5.846.
Reference Type
BACKGROUND
Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost. 2004 Dec;2(12):2118-32. doi: 10.1111/j.1538-7836.2004.00968.x.
Reference Type
BACKGROUND
Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost. 2007 Jul;98(1):120-5.
Reference Type
BACKGROUND
McCann JC, Ames BN. Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging? Am J Clin Nutr. 2009 Oct;90(4):889-907. doi: 10.3945/ajcn.2009.27930. Epub 2009 Aug 19.
Reference Type
BACKGROUND
Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care. 2000 Nov;3(6):433-8. doi: 10.1097/00075197-200011000-00004.
Reference Type
BACKGROUND
Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL. The role of Gla proteins in vascular calcification. Crit Rev Eukaryot Gene Expr. 1998;8(3-4):357-75. doi: 10.1615/critreveukargeneexpr.v8.i3-4.60.
Reference Type
BACKGROUND
Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007 Apr 1;109(7):2823-31. doi: 10.1182/blood-2006-07-035345.
Reference Type
BACKGROUND
Li Q, Guo H, Chou DW, Harrington DJ, Schurgers LJ, Terry SF, Uitto J. Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticum. Am J Pathol. 2013 Apr;182(4):1139-50. doi: 10.1016/j.ajpath.2012.12.037. Epub 2013 Feb 15.
Reference Type
BACKGROUND
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997 Mar 6;386(6620):78-81. doi: 10.1038/386078a0.
Reference Type
BACKGROUND
Theuwissen E, Smit E, Vermeer C. The role of vitamin K in soft-tissue calcification. Adv Nutr. 2012 Mar 1;3(2):166-73. doi: 10.3945/an.111.001628.
Reference Type
BACKGROUND
Shea MK, O'Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, Ordovas JM, Price PA, Williamson MK, Booth SL. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr. 2009 Jun;89(6):1799-807. doi: 10.3945/ajcn.2008.27338. Epub 2009 Apr 22.
Reference Type
BACKGROUND
Vermeer C, Shearer MJ, Zittermann A, Bolton-Smith C, Szulc P, Hodges S, Walter P, Rambeck W, Stocklin E, Weber P. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr. 2004 Dec;43(6):325-35. doi: 10.1007/s00394-004-0480-4. Epub 2004 Feb 5.
Reference Type
BACKGROUND
Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, Witteman JC. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004 Nov;134(11):3100-5. doi: 10.1093/jn/134.11.3100.
Reference Type
BACKGROUND
Gast GC, de Roos NM, Sluijs I, Bots ML, Beulens JW, Geleijnse JM, Witteman JC, Grobbee DE, Peeters PH, van der Schouw YT. A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis. 2009 Sep;19(7):504-10. doi: 10.1016/j.numecd.2008.10.004. Epub 2009 Jan 28.
Reference Type
BACKGROUND
Beulens JW, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM, Witteman JC, Grobbee DE, van der Schouw YT. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009 Apr;203(2):489-93. doi: 10.1016/j.atherosclerosis.2008.07.010. Epub 2008 Jul 19.
Reference Type
BACKGROUND
Brandenburg VM, Schurgers LJ, Kaesler N, Pusche K, van Gorp RH, Leftheriotis G, Reinartz S, Koos R, Kruger T. Prevention of vasculopathy by vitamin K supplementation: can we turn fiction into fact? Atherosclerosis. 2015 May;240(1):10-6. doi: 10.1016/j.atherosclerosis.2015.02.040. Epub 2015 Feb 24.
Reference Type
BACKGROUND
Caluwe R, Pyfferoen L, De Boeck K, De Vriese AS. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kidney J. 2016 Apr;9(2):273-9. doi: 10.1093/ckj/sfv146. Epub 2015 Dec 29.
Reference Type
BACKGROUND
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015 Aug 7;21(29):8787-803. doi: 10.3748/wjg.v21.i29.8787.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018/79
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Implications of the Human Microbiota for Health and Disease
NCT04203303
RECRUITING
Study of the Intestinal Microbiota
NCT07058961
RECRUITING
Intestinal Microbiota Composition After Antibiotic Treatment in Early Life
NCT02536560
UNKNOWN
Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.
NCT02031588
TERMINATED
Acute Microbial Switch
NCT05764200
RECRUITING
NA
Can the Relative Fecal Abundance of BLSE and the Digestive Microbiota be Predictive of the Risk of Infection in a Carrier Patient?
NCT04699981
UNKNOWN
NA
Epidemiological Study of Intestinal Colonization With Staphylococcus Aureus
NCT02547272
COMPLETED
PCT REveals Good Recovery After Acute Diverticulitis: the PREGRAD Study
NCT02817854
UNKNOWN
Fecal Microbiota Transplantation (FMT) to Decolonize Antibiotic - Resistant Bacteria (ARB) - New Protocol
NCT06156956
RECRUITING
NA
Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae on Admission to a French University Teaching Hospital
NCT05798351
RECRUITING
Identification of Gut Microbiome Biomarkers Associated to Acquisition of Enterobacteriae Highly Resistant to Third Generation Cephalosporines Following Ceftriaxone Treatment.
NCT03569917
TERMINATED
NA
Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome
NCT05302531
RECRUITING
PHASE1
Microbiota Study in Liver Transplanted Patients
NCT03507140
COMPLETED
WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
NCT01587768
COMPLETED
Assessing the Performance of Shotgun Metagenomics in the Diagnosis of Complex Prosthetic Joint Infections
NCT06062251
RECRUITING
Collection of Microbiome Samples of Healthy Western Donors for Fundamental and Functional Microbiome Research
NCT06466707
RECRUITING
NA
Integrated Genetic and Functional Analysis of the Female Microbiome in a Flemish Cohort
NCT04319536
UNKNOWN
PRObing The Efficacy of Commercial Stage Storage Buffers and Evaluating Gut Metaproteome Variability Between Individuals
NCT06423508
RECRUITING
Impact of Three Probabilistic Antibiotic Therapy on Digestive Microbiota and Colonization With Multi-resistant Bacteria
NCT07058415
NOT_YET_RECRUITING
NA
Recurrent ESBL-producing Enterobacteriaceae Bacteremia: Risk Factor, Molecular Character and Susceptibility Change
NCT01392118
UNKNOWN
Multi-Antibiotic Resistance Carriage in Gut Flora
NCT01591538
COMPLETED
A Clinical Study With the Medical Device PowerSpiral for Deep Enteroscopy
NCT03955081
COMPLETED
Prevalence of Digestive Carriage of Integrons
NCT01985217
COMPLETED
Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia
NCT06833593
RECRUITING
Fecal Microbiota Transplantation (FMT) in the Treatment of Pouchitis
NCT03378921
COMPLETED
PHASE2